Cart
sales@molnova.com
Home -
Products -
Angiogenesis -
PDE -
2,5-dichloro-4-(difluoromethoxy)-N,N-dimethylbenzene-1-sulfonamide
2,5-dichloro-4-(difluoromethoxy)-N,N-dimethylbenzene-1-sulfonamide
CAS No. 473477-26-8
2,5-dichloro-4-(difluoromethoxy)-N,N-dimethylbenzene-1-sulfonamide( —— )
Catalog No. M28427 CAS No. 473477-26-8
2,5-dichloro-4-(difluoromethoxy)-N,N-dimethylbenzene-1-sulfonamide is a PDE inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 104 | In Stock |
|
| 2MG | 65 | In Stock |
|
| 5MG | 100 | In Stock |
|
| 10MG | 149 | In Stock |
|
| 25MG | 256 | In Stock |
|
| 50MG | 367 | In Stock |
|
| 100MG | 524 | In Stock |
|
| 200MG | 713 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name2,5-dichloro-4-(difluoromethoxy)-N,N-dimethylbenzene-1-sulfonamide
-
NoteResearch use only, not for human use.
-
Brief Description2,5-dichloro-4-(difluoromethoxy)-N,N-dimethylbenzene-1-sulfonamide is a PDE inhibitor.
-
Description2,5-dichloro-4-(difluoromethoxy)-N,N-dimethylbenzene-1-sulfonamide is a PDE inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorHSP90
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number473477-26-8
-
Formula Weight320.13
-
Molecular FormulaC9H9Cl2F2NO3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCN(C)S(=O)(=O)c1cc(Cl)c(OC(F)F)cc1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Park S, et al. The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells. Cell Death Discov. 2021;7(1):354.
molnova catalog
related products
-
N-Ethyl tadalafil
N-Ethyl tadalafil (NEthyl tadalafil) is a CGMP-specific 3',5'-cyclic phosphodiesterase (PDE) inhibitor used in the study of cardiovascular diseases such as angina pectoris, hypertension, and pulmonary hypertension.
-
Anagrelide
Anagrelide is a Platelet-reducing Agent. The mechanism of action of anagrelide is as a Phosphodiesterase 3 Inhibitor.
-
Triflusal
Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981.
